Phuturdex › Diseases › Fibrosis
Drugs in development · updated 30 October 2026
Fibrosis: drugs in development
As of 30 October 2026 there are 51 active clinical trials (recruiting or ongoing, phases I–III) on 52 drugs for fibrosis. 18 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Mosliciguat | III | 3 | NCT07816185 |
| Efimosfermin alfa | III | 2 | NCT07701993 |
| Pegozafermin | III | 2 | NCT06419374 |
| BMS-986278 | III | 1 | NCT06025578 |
| IVA337 | III | 1 | NCT04849728 |
| Namodenoson | III | 1 | NCT05201404 |
| [68Ga]CBP8 | II | 1 | NCT04485286 |
| Efimosfermin | II | 1 | NCT06920043 |
| Efzofitimod | II | 1 | NCT05892614 |
| INS018_055 | II | 1 | NCT05975983 |
| ME-015 | II | 1 | NCT05983471 |
| MTX-463 | II | 1 | NCT06967805 |
| Pirfenidoneone | II | 1 | NCT06912763 |
| RTX001 | I–II | 1 | NCT06823713 |
| RXC007 | II | 1 | NCT05570058 |
| ZanzalintinibXL092 | I–II | 1 | NCT07042919 |
| Artesuante | I | 1 | NCT05988463 |
| Saroglitazar Magnesium | I | 1 | NCT05045482 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| ResmetiromMGL-3196, Rezdiffra® | III | 3 | NCT04951219 |
| Angiotensin II | II–III | 1 | NCT04901169 |
| AspirinVazalore®, Durlaza® | III | 1 | NCT07529262 |
| Bisacodyl | III | 1 | NCT07668778 |
| BumetanideEnbumyst®, Bumex® | III | 1 | NCT06941415 |
| EsmololEsmolol Hydrochloride Double Strength In Plastic Container®, Esmolol Hydrochloride In Plastic Container® | III | 1 | NCT05769868 |
| FurosemideLasix Onyu®, Furoscix® | III | 1 | NCT06941415 |
| MemantineNamenda, Memantine Mylan® | II–III | 1 | NCT06007846 |
| SimvastatinFlolipid®, Zocor® | III | 1 | NCT03654053 |
| AtorvastatinLipitor, Atorvaliq® | II | 2 | NCT05028829 |
| Pentoxifyllinepentoxyifylline, Trental® | II | 2 | NCT06494111 |
| PravastatinPravachol® | II | 2 | NCT06494111 |
| Tocopherol | II | 2 | NCT06494111 |
| AmitriptylineElavil® | II | 1 | NCT05120934 |
| ApixabanEliquis, Abanta® | II | 1 | NCT05869591 |
Sorted by most advanced phase and number of active trials. Showing 15 of 34 drugs.
All 52 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Liver Cirrhosis, Biliary 13 drugs
- Liver cirrhosis 38 drugs
- Pulmonary fibrosis 34 drugs
- Idiopathic pulmonary fibrosis 57 drugs
- Interstitial lung disease 65 drugs
- Hepatocellular carcinoma 266 drugs
- Non-alcoholic Fatty Liver Disease 68 drugs
- Pruritus 18 drugs
- Lung disease 104 drugs
- Cicatrix 4 drugs
- Idiopathic interstitial pneumonia 4 drugs
- Sclerosing cholangitis 17 drugs
Broader categories
- Digestive System Diseases 36 drugs
- Liver disease 33 drugs
- Respiratory disease 57 drugs
- Lung disease 104 drugs
- Neoplasm 671 drugs
- Glandular and epithelial neoplasm 12 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D005355 “Fibrosis”.